# COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

> **NCT06372457** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 331 (actual)

## Conditions studied

- Hypertrophic Cardiomyopathy (HCM)

## Interventions

- **DRUG:** Approved Hypertrophic Cardiomyopathy drug treatments
- **DRUG:** Mavacamten

## Key facts

- **NCT ID:** NCT06372457
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2025-09-29
- **Final completion:** 2026-06-30
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372457, "COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06372457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*